- A new class action complaint has been filed against aTyr Pharma, Inc. and its executives, expanding the alleged class period for securities litigation to cover **November 7, 2024, through September 12, 2025**.  **[1339970_20251030SF10943:0]** 
- The lawsuit alleges that aTyr made false and misleading statements about the efficacy of its drug, Efzofitimod, in its Phase 3 EFZO-FIT study.  **[1339970_20251030SF10943:0]** 
- This follows a **one-day decline of 83.2%** in ATYR's stock price on September 15, 2025, after the company announced the EFZO-FIT study did not meet its primary endpoint.  **[1339970_20251030SF10943:0]** 
- The lead plaintiff deadline for investors is **December 8, 2025**.  **[1339970_20251030SF10943:0]**

aTyr Pharma Faces Expanded Securities Class Action

- A new class action complaint has been filed against **aTyr Pharma, Inc. (NASDAQ: ATYR)** and certain executives, significantly enlarging the alleged class period for investors.  **[1339970_deeb3460ff1549bea7a95233a533131d_0]** 
- The lawsuit alleges that aTyr made false and misleading statements about the efficacy of its drug, **Efzofitimod**, leading investors to purchase stock at artificially inflated prices.  **[1339970_deeb3460ff1549bea7a95233a533131d_0]** 
- The expanded alleged class period covers investors who acquired aTyr Pharma securities between **November 7, 2024, and September 12, 2025**, inclusive.  **[1339970_deeb3460ff1549bea7a95233a533131d_0]** 
- The core of the allegations stems from the company's announcement on **September 15, 2025**, that its Phase 3 EFZO-FIT study for Efzofitimod did not meet its primary endpoint.  **[1339970_deeb3460ff1549bea7a95233a533131d_0]** 
- Following this announcement, aTyr's common stock experienced a **catastrophic one-day decline of 83.2%** on September 15, 2025, closing at **$1.02 per share** from $6.03 per share on the preceding Friday.  **[1339970_deeb3460ff1549bea7a95233a533131d_1]**

aTyr Pharma Faces Expanded Securities Class Action Lawsuit

- A new class action complaint has been filed against **aTyr Pharma, Inc. (NASDAQ: ATYR)** and its executives, significantly enlarging the alleged class period to **November 7, 2024, through September 12, 2025**.  **[1339970_20251024SF06392:0]** 
- The lawsuit alleges that aTyr made **false and misleading statements** regarding the efficacy of its drug, **Efzofitimod**, specifically its ability to allow patients to completely taper steroid usage in the Phase 3 EFZO-FIT study.  **[1339970_20251024SF06392:0]** 
- On **September 15, 2025**, aTyr announced that the EFZO-FIT study did not meet its primary endpoint, which led to a **catastrophic one-day decline of 83.2%** in its common stock, from **$6.03 to $1.02 per share**.  **[1339970_20251024SF06392:0]** 
- The **Lead Plaintiff Deadline** for investors who suffered substantial losses is **December 8, 2025**.  **[1339970_20251024SF06392:0]**

- A federal class-action lawsuit has been filed against aTyr Pharma, Inc. (ATYR) by Hagens Berman following an **83% drop** in its stock price after its lead drug candidate failed to meet its primary endpoint in a Phase 3 trial.  **[1339970_20251021SF02727:0]** 
- The lawsuit alleges that aTyr and its top executives made false and misleading statements about the efficacy of its drug, **Efzofitimod**, leading investors to purchase stock at artificially inflated prices.  **[1339970_20251021SF02727:0]** 
- The proposed class covers investors who acquired aTyr common stock between **January 16, 2025, and September 12, 2025**.  **[1339970_20251021SF02727:0]** 
- The stock price plummeted from **$6.03** to **$1.02** per share on **September 15, 2025**, after the announcement that the EFZO-FIT study did not meet its primary endpoint.  **[1339970_20251021SF02727:0]** 
- The Lead Plaintiff Deadline for the lawsuit is **December 8, 2025**.  **[1339970_20251021SF02727:0]**

aTyr Pharma Faces Securities Lawsuit After Failed Drug Trial

- A federal class-action lawsuit has been filed against aTyr Pharma, Inc. (ATYR) after its lead drug candidate, Efzofitimod, **failed to meet its primary endpoint** in a Phase 3 trial, leading to an **83% drop** in the company's stock price.  **[1339970_ec38efb1153546f1a8d8fcc8619ddbe9_0]** 
- The lawsuit, _Munguia v. aTyr Pharma Inc._, alleges that aTyr and its executives made **false and misleading statements** about Efzofitimod's efficacy, causing investors to purchase stock at artificially inflated prices between **January 16, 2025, and September 12, 2025**.  **[1339970_ec38efb1153546f1a8d8fcc8619ddbe9_0]** 
- The EFZO-FIT study, which evaluated Efzofitimod for pulmonary sarcoidosis, did not meet its primary endpoint of change from baseline in mean daily oral corticosteroid dose at week 48.  **[1339970_ec38efb1153546f1a8d8fcc8619ddbe9_0]** 
- Following the announcement on **September 15, 2025**, aTyr's common stock plummeted from **$6.03** per share to **$1.02** per share.  **[1339970_ec38efb1153546f1a8d8fcc8619ddbe9_0]** 
- Hagens Berman is investigating whether aTyr may have misled investors about its data and trial design.  **[1339970_ec38efb1153546f1a8d8fcc8619ddbe9_1]**

aTyr Pharma Faces Securities Lawsuit Following Failed Drug Trial

- A federal class-action lawsuit has been filed against aTyr Pharma, Inc. (ATYR) following an **83% drop** in its stock price after its lead drug candidate, Efzofitimod, failed to meet its primary endpoint in a Phase 3 trial.  **[1339970_20251017SF00477:0]** 
- The lawsuit alleges that aTyr and its top executives made **false and misleading statements** about the efficacy of Efzofitimod, leading investors to purchase stock at artificially inflated prices.  **[1339970_20251017SF00477:0]** 
- The proposed class covers investors who acquired aTyr common stock between **January 16, 2025, and September 12, 2025**, with a Lead Plaintiff Deadline of **December 8, 2025**.  **[1339970_20251017SF00477:0]**

- A federal class-action lawsuit has been filed against **aTyr Pharma, Inc. (ATYR)** following an **83% drop** in its stock price.  **[1339970_f328066c4df24730bcce51de9149c289_0]** **[1339970_f328066c4df24730bcce51de9149c289_1]** 
- This significant stock decline occurred after its lead drug candidate, **Efzofitimod**, failed to meet its primary endpoint in a critical Phase 3 trial (EFZO-FIT study).  **[1339970_f328066c4df24730bcce51de9149c289_0]** **[1339970_f328066c4df24730bcce51de9149c289_1]** 
- The lawsuit alleges that aTyr and its top executives made **false and misleading statements** about Efzofitimod's efficacy, leading investors to purchase stock at artificially inflated prices.  **[1339970_f328066c4df24730bcce51de9149c289_1]** 
- The proposed class covers investors who acquired aTyr common stock between **January 16, 2025, and September 12, 2025**, with a Lead Plaintiff Deadline of **December 8, 2025**.  **[1339970_f328066c4df24730bcce51de9149c289_1]**

aTyr Pharma Faces Securities Lawsuit After Lead Drug Candidate Fails Phase 3 Trial

- A federal class-action lawsuit has been filed against **aTyr Pharma, Inc. (ATYR)** following an **83% drop** in its stock price after its lead drug candidate, Efzofitimod, failed to meet its primary endpoint in a critical Phase 3 trial.  **[1339970_793723d56b9649a3aaf3d772bf59c82e_0]** 
- The lawsuit alleges that aTyr and its top executives made **false and misleading statements** about Efzofitimod's efficacy, leading investors to purchase stock at artificially inflated prices.  **[1339970_793723d56b9649a3aaf3d772bf59c82e_0]** 
- The proposed **Class Period** for the lawsuit is **January 16, 2025 – September 12, 2025**.  **[1339970_793723d56b9649a3aaf3d772bf59c82e_0]** 
- The EFZO-FIT study, which evaluated intravenous Efzofitimod in patients with pulmonary sarcoidosis, did not meet its primary endpoint of change from baseline in mean daily oral corticosteroid dose at week 48.  **[1339970_793723d56b9649a3aaf3d772bf59c82e_0]**

- A securities class action lawsuit has been filed against **aTyr Pharma Inc. (NASDAQ: ATYR)** by Gainey McKenna & Egleston.  **[1339970_f5375a9e5cec4b5d94e7d159458f9fdb_0]** 
- The lawsuit covers the **Class Period** from **January 16, 2025, to September 12, 2025**.  **[1339970_f5375a9e5cec4b5d94e7d159458f9fdb_0]** 
- The complaint alleges that aTyr made false and misleading statements regarding the efficacy of its drug **Efzofitimod** in the **EFZO-FIT study**, particularly its capability to allow patients to completely taper steroid usage.  **[1339970_f5375a9e5cec4b5d94e7d159458f9fdb_0]** 
- The lawsuit was initiated after aTyr announced on **September 15, 2025**, that the **EFZO-FIT study did not meet its primary endpoint**.  **[1339970_f5375a9e5cec4b5d94e7d159458f9fdb_0]** 
- The lead plaintiff motion deadline for investors is **December 8, 2025**.  **[1339970_f5375a9e5cec4b5d94e7d159458f9fdb_0]**

Gainey McKenna & Egleston Announces Class Action Lawsuit Against aTyr Pharma

- A federal class-action lawsuit has been filed against aTyr Pharma, Inc. (ATYR) following an **83% drop** in its stock price.  **[1339970_20251009SF94938:0]** 
- The stock decline occurred after the company's lead drug candidate, Efzofitimod, **failed to meet its primary endpoint** in a Phase 3 trial for pulmonary sarcoidosis.  **[1339970_20251009SF94938:0]** 
- The lawsuit alleges that aTyr and its executives made **false and misleading statements** about the drug's efficacy, leading investors to purchase stock at artificially inflated prices.  **[1339970_20251009SF94938:0]** 
- The proposed class period for the lawsuit is **January 16, 2025, to September 12, 2025**, with a lead plaintiff deadline of **December 8, 2025**.  **[1339970_20251009SF94938:0]**

aTYR PHARMA (ATYR)